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Abstract
The primary purpose of this paper is to investigate the mechanics of Aβ protein aggregation
within the brain through mathematical modeling and simulation. Aggregation of Aβ is the
cause of plaques within the brain of Alzheimer’s Disease sufferers. Because the pathways of
aggregation from monomer to oligomer to polymer are numerous and complex, we have had
to simplify our model to a limited number of species. Of great concern, too, is the process
by which Aβ can form as “off-pathway” species, which is when Aβ reacts with fatty acid
micelles. It is this species of Aβ, which due to its toxicity to neurons, that is now believed
to cause Alzheimer’s Disease.
Although the precise mechanism of Aβ aggregation continues to be heavily debated,
evidence suggests a rate-limiting mechanism. Thus we will use Mass Action Kinetics to
write a system of differential equations for the purpose of simulating aggregation of the Aβ
protein in its different forms. We will analyze the stability of the system under different
reaction rate regimes, as well as the system’s preferences for particular equilibrium states.
Finally, we will examine the thermodynamics of the system.
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Chapter 1
Introduction
1.1 Motivation
According to the Fisher Center for Alzheimer’s Research, 30 million people live with
Alzheimer’s Disease (AD) worldwide, and the number is expected to reach 60 million people
by 2030 [1]. Alzheimers Disease can occur in people as young as their early 40’s (Early
Onset), but these cases represent only 5% of the total. Most AD cases occur in people in
their mid-60’s and on, with approximately 10% of the population at risk of contracting the
disease in that age group. By some estimates, by the time a person reaches their mid-80’s,
there is a 50% chance of having AD. Thus have improvements in health and longevity been
a mixed blessing. According to the Alzheimer’s Association, the average duration of the
disease is 7 years, and once contracted progressively worsens, ultimately resulting in death.
There is currently no cure.
The Alzheimer’s Association recently reported that the cost of care for people with AD
in the US will consume 25% of Medicare spending by the middle of the century. In 2010
alone, the total, direct cost of AD care in the US was $157 billion, or approximately $50,000
per patient. These figures, while of concern on their own, don’t count the indirect burden
of AD care exacted upon loved ones and caregivers. For those who cannot afford nursing
home care, looking after a family member with AD can be an all-consuming job. Therefore,
the number of people affected by AD is much larger than the 30 million who actually have
the disease. In many developed countries, with the aging of populations, these social and
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financial costs will only continue to increase.
Thus, from both a public health and a fiscal health perspective, Alzheimer’s Disease is a
major challenge worldwide. The need for research is therefore vitally important. While we
are enabling people to live longer, this increased longevity comes at a great cost in terms of
caring for a significant proportion of the elderly population who are incapacitated, not to
mention the diminished quality of life of those suffering from AD. It is these concerns that
have motivated our research.
1.2 History of AD
The identification of the causes of dementia is credited to Alois Alzheimer. In 1907,
while performing an autopsy on a woman who had died from a progressive behavioral and
cognitive disorder, Alzheimer noted the presence of two pathologies: neurofibrillary tangles
and neuritic plaques [2]. Neurons are cells that transmit nerve impulses, or information,
throughout the body, and the tangles were essentially deformed neurons. The plaques were
extra-cellular deposits found throughout the brain. Subsequent research down the years
has shown that these tangles are related to the protein tau and the neuritic plaques are
aggregations of the amyloid-β peptide (Aβ) [2]. In our research, we will be modeling the
latter pathology: the formation of Aβ plaques.
1.3 The Biophysics of AD
At the outset it should be noted that much of what we “know” about the role of Aβ
or the causes of AD are heavily debated. In fact, scientists have long been puzzled by the
weak link between the amount of Aβ deposition and the degree of dementia, not to mention
the uncertainty as to which form of Aβ causes AD [3]. AD sufferers all have the plaques,
however not all people with the plaques necessarily had AD. The process of aggregation from
monomer to oligomer is also poorly understood [4]. This lack of understanding is due in part
to two major problems with AD research: first, early diagnosis at this point is inexact and
unreliable, and secondly, measuring the amount of Aβ plaque deposition occurs only post
mortem [3]. Thus, accurately tracking the progression of the disease in humans is virtually
impossible at this time. With that said, the following is a brief outline of what can best be
described as the consensus view.
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Alzheimer’s Disease is one in a class of protein folding disorders called amyloidosis [1].
Amyloid Precursor Protein (APP) is produced in large quantities in the brain, and is believed
to play an important role in healthy cell functioning. APP is broken down into monomers
(single units) of amino acids by the action of beta and gamma secretase enzymes. It is
these amino acids that can aggregate to form Aβ peptides (or oligomers), which are strings
of these amino acids. These peptides form extracellular deposits, or plaques, which are
believed to be toxic to neurons. Aβ40 is the most abundant, but it is Aβ42, which due to its
hydrophobic and fibrillogenic nature, that is responsible for plaque deposition in AD brains.
Recent evidence, however, seems to implicate an intermediate form of Aβ, which is soluble,
as the cause of AD rather than the plaques themselves. It is this “off-pathway” aggregation
of the soluble form of Aβ that is now thought to be the neurotoxic agent[3].
Thus, aggregation of Aβ, in some form, is believed to constitute the central process in
the AD pathology. Brains of AD patients contain large amounts of plaques that are mainly
comprised of insoluble Aβ fibril deposits.
Figure 1.1: Plaque Deposits in AD Brain.
Monomeric Aβ peptides (Aβ40 and Aβ42 ) spontaneously undergo self-assembly towards
large fibrils in a nucleation dependent manner. Although the precise mechanism of nucleation
continues to be heavily debated, substantial evidence suggests a rate-limiting mechanism for
the formation of nucleus or nuclei [5; 6; 7; 8; 9]. The dynamics associated with reactions
leading up to nucleation is critical for aggregation. Energetically, the pre-nucleation phase
is nebulous with monomers and oligomers (dimers, trimers etc.) being in dynamic flux in-
volving stochastic interactions [10; 11; 12]. Intrinsic disorder and amphipathic nature of
monomeric Aβ also facilitate significant phase transitions and heterogeneous interactions
during nucleation, making the process particularly sensitive to environmental factors such as
pH, ionic strength, temperature and other interacting partners [13; 15; 16; 17; 18]. This is sig-
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nificant because smaller, soluble aggregates have emerged as the primary neurotoxic agents
responsible for memory loss in AD [19; 20; 21; 22]. Furthermore, it is clear that oligomers
may not be obligatory intermediates to fibril formation, and that the oligomers can also be
populated along alternate pathways of aggregation (off-pathways) [23; 24; 25; 26; 27; 28].
As previously mentioned, off-pathway oligomers may differ from those formed along the on-
pathway resulting in multiple conformational variants with distinct biochemical and cellular
properties. Given the conformational diversity among oligomers, it is imperative to deter-
mine the factors that affect dynamics involved in their formation to establish a framework
of molecular mechanisms that better defines amyloid progression.
Some of such biologically significant interacting partners that could affect Aβ pre-nucleation
dynamics are anionic surfactants such as fatty acids and lipids [29; 30; 31; 32; 33; 34; 35].
Interfaces of lipids and fatty acids are of profound interest in physiological contexts as they
are abundant in both cerebral vasculature and CSF [36; 37]. Amphipathic Aβ peptide is
known to have strong affinity for membranes and hence, these interactions may affect early
steps of aggregation. Several reports also show the effects of phospholipids on Aβ aggrega-
tion [38; 39; 40]. Similarly, polyunsaturated (PUFAs) as well as saturated fatty acids are also
known to have a significant effect on AD brain [41; 42]. In previous publications, our collabo-
rators have also reported the generation of 4-5mers and 12-24mers from lauric acid interfaces
along a non-fibril formation pathway [18]. More importantly, using carbon chain lengths of
C9-C12 fatty acids, we established that below (non-micellar), near (pseudo-micellar) and
above (micellar) their critical micelle concentrations, they generate Aβ oligomers or fibrils
via distinct pathways [18].
There are 3 main sections to this report. In the first section, we examine a reduced-order
4 species model. Using Mass Action Kinetics, we formulate a system of differential equations
that model the chemical reactions between these four species. We then examine the stability
of the system to verify the validity of the model and the appropriateness of our parameters.
We also study the evolution of the model and its equilibria under various rate regimes. Our
collaborators at Virginia Commonwealth University have created a much larger and more
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complicated version of our system. Our approach has been to simplify this system so that
we can focus on a limited number of parameters that determine the pathways of Aβ ag-
gregation. Other recent work along the lines of mathematical modeling of Aβ aggregation
includes that done by Murphy and Knowles. What sets our work apart from these is our
analysis of stability, modeling of species evolution over time, and our use of a game theoretic
approach to competition between species.
In the second part, we will look at a six species model where we will again analyze the
stability and numerical results. By adding two more species to the model, we add another
path leading to off-pathway aggregation, thus adding more complexity to the system while
keeping its essential simplicity. In the third part, we will analyze the thermodynamics of the
system.
What follows is an investigation into mathematically modeling the aggregation process of
Aβ. The major obstacle to investigating AD is the lack of understanding of the progression
of the disease. Therefore, comparing our model to actual data is impossible at this point.
Thus we have had to content ourselves with a purely mathematical analysis. Although we
are not presuming to recommend therapies or direct courses of action to cure Alzheimer’s,
the hope is to gain a greater understanding of what could be happening inside the brain
of an AD sufferer. Our models are simplified versions consisting of 4 and then 6 species
of Aβ with the objective of understanding the dynamics of the system on a rudimentary
level. Even with just 6 species, however, there are infinitely many rate regimes that we
could investigate, most of which would be physically meaningless. Thus, we have not made
an exhaustive sweep of all parameter values, but have chosen to experiment with physically
meaningful rate regimes about which we have varied our key parameters. The goal is to
gain a greater understanding of how to mathematically model Aβ aggregation and hopefully
make a contribution to solving what is becoming a serious health care crisis.
12
Chapter 2
Four Species Model
2.1 The Model
We examine the sets of on- and off-pathway reactions shown below. The model system
is as follows:
A1 + L
k+1
k−1
A′1
n ·A1
k+2
k−2
An
n ·A′1
k+3
k−3
A′n
We use the Law of Mass Action Kinetics to formulate our system of differential equa-
tions. For example, if we take the second chemical reaction that describes the aggregation
of molecules of the species A1 into an n-mer, An,
n ·A1
k+2
k−2
An
and consider just the forward reaction,
n ·A1 k
+
2⇀ An
the left side are the reactants, and the right side are the products, with k+2 being the reaction
rate constant. In a reaction, the stoichiometric coefficients, in this case n, become exponents
[44]. If we add the backward reaction, this coupled system would be expressed as:
dA1
dt
= nk−2 An − nk+2 An1 (2.1)
dAn
dt
= −k−2 An + k+2 An1 (2.2)
13
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In similar fashion, the entire system of the above reactions would be expressed as,
dA1
dt
= nk−2 An − nk+2 An1 + k−1 A′1 − k+1 A1L (2.3)
dA′1
dt
= nk−3 A
′
n − nk+3 A′n1 − k−1 A′1 + k+1 A1L (2.4)
dAn
dt
= −k−2 An + k+2 An1 (2.5)
dA′n
dt
= −k−3 A′n + k+3 A′n1 (2.6)
that are better suited for analysis in non-dimensional form. If we chose the characteristic
concentration and time as A0 (the equilibrium concentration of monomers) and
1
k−1
, respec-
tively, then the dimensionless variables can be defined as,
B1 =
A1
A0
;B′1 =
A′1
A0
;Bn =
An
A0
;B′n =
A′n
A0
α1 =
k−2
k−1
;α2 =
k+2 A
n−1
0
k−1
;α3 =
k+1 L
k−1
;β1 =
k−3
k−1
;β2 =
k+3 A
n−1
0
k−1
; (2.7)
the corresponding dimensionless differential equations of which can now can be written as,
dB1
ds
= nα1Bn − nα2Bn1 +B′1 − α3B1 (2.8)
dB′1
ds
= nβ1B
′
n − nβ2B′n1 + α3B1 −B′1 (2.9)
dBn
ds
= α2B
n
1 − α1Bn (2.10)
dB′n
ds
= β2B
′n
1 − β1B′n (2.11)
Figure 2.1: Schematic of the system with backward and forward rates.
2.2 Equilibrium points
In the equations (2.3)-(2.6), if we consider the limit (k+1 , k
−
1 , L) → (0, 0, 0), then the
off-pathway dynamics is turned off, leaving only the reaction below.
n ·A1
k+2
k−2
An
14
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However, the on-pathway cannot be switched off and always persists. In this case the equi-
librium solution is given by the pair
(
A1,e,
(
k+2
k−2
A1,e
)1/n)
. In the more general case of
equations (2.8)-(2.11), the equilibrium points, Be =
(
B1,e, B
′
1,e, Bn,e, B
′
n,e
)
can be obtained
by the vanishing of the equations 2.8-2.11. Solving for these four simultaneous equations,
we obtain the following relations, in terms of the equilibrium concentration B1,e:
Bn,e =
α2
α1
Bn1,e; B
′
1,e = α3B1,e; B
′
n,e =
β2α
n
3
β1
Bn1,e. (2.12)
The substricpt e indicates that these species are in equilibrium.
2.3 Linear Stability Analysis
When formulating a system of differential equations, it’s important to analyze the sta-
bility of the system. Specifically, we are interested in the effect upon the system of small
changes in initial conditions. Do these changes have a negligible effect on the solutions, or
do they result in dramatic changes? The method used to determine this is linear stability
analysis. The idea is to perturb the system with a small change  > 0 to the initial con-
ditions and then linearize the perturbed system at our equilibrium point to determine the
trajectories at that point. The method involves writing the Jacobian matrix of the system
evaluated at the fixed, or equilibrium, point. The eigenvalues of the Jacobian are the solu-
tions of the linearized system at this point, those being exponentials whose powers are the
eigenvalues. Negative eigenvalues mean that the perturbation decays to zero, or converges
to the equilibrium point, while positive eigenvalues mean that the system moves infinitely
away from the equilibrium point over time.
There are three general classifications of fixed points for a system of differential equations:
a fixed point is asymptotically stable if all of the eigenvalues are negative, unstable if just one
of the eigenvalues are positive, and neutrally stable if the eigenvalues are complex with real
parts less than or equal to zero. When the eigenvalues all have the same sign, the fixed point
is a node which can be stable or unstable depending on the sign of the eigenvalues. When
the eigenvalues differ in sign, the fixed point is a saddle point which is unstable. Complex
eigenvalues just add oscillations and are called spiral points, which again can be stable or
15
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unstable depending upon the sign of the real part. In the case when there are zero real parts
(with none being positive), the fixed point is a center, and is considered neutrally stable:
small perturbations neither decay to the equilibrium point nor do they diverge infinitely
away from the equilibrium point.
To study the stability of the four species, we linearly perturb the system which is math-
ematically represented by
B1 = B1,e + X1 (2.13)
B′1 = B
′
1,e + Y1 (2.14)
Bn = Bn,e + Xn (2.15)
B′n = B
′
n,e + Yn (2.16)
(2.17)
then the linearized set of differential equations for the perturbations, at o() becomes
dX1
dt
= nα1Xn − n2α2Bn−11,e X1 + Y1 − α3X1 (2.18)
dY1
dt
= nβ1Yn − n2β2αn−13 Bn−11,e Y1 − Y1 + α3X1 (2.19)
dXn
dt
= nα2B
n−1
1,e X1 − α1Xn (2.20)
dYn
dt
= β2α
n−1
3 B
n−1
1,e Y1 − β1Yn (2.21)
which can be expressed in operator form with the perturbation matrix B given by
B =
⎛
⎜⎜⎜⎜⎜⎜⎜⎝
−n2α2Bn−11,e − α3 1 nα1 0
α3 −n2β2αn−13 Bn−11,e − 1 0 nβ1
nα2B
n−1
1,e 0 −α1 0
0 β2α
n−1
3 B
n−1
1,e 0 −β1
⎞
⎟⎟⎟⎟⎟⎟⎟⎠
The matrix B is the Jacobian which is evaluated at the equilibrium point given by 2.12.
The stability of the equilibrium is found from computing the eigenvalues, λi (i = 1, 2, 3, 4)
of the matrix B. This is best done numerically. In the figures below we discuss the results
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of the computations. In particular, the term α3 is varied throughout the analysis since it
captures a significant dynamical feature of this problem; the switching from on-pathway to
off-pathway. Over all, we choose the following ranges for our parameters: 0 ≤ α3 ≤ 2 for
i = 1, 2; 2 ≤ n ≤ 20; and 10−3 ≤ αi, βi ≤ 2 × 103 for i = 1, 2. We begin with the base case
defined by the choice α1 = β1 = 0.001, α2 = β2 = 1, n = 4 and B1 = 1 and then study the
sensitivity of the system and our results to each of the parameters.
Figure 2.2: The eigenvalues of matrix B as a function of α3. Case (a) shows the switching
event at a critical value of α3 while panel (b) shows the eigenvalues to the on- and off-
pathways.
The figure 2.3 shows a significant event in the dynamics of this system. As α3 is increased
from zero, the real part of the eigenvalues λi are all negative, indicating that the equilibria
are stable. When α3 < 1.0, we see that λ2 > λ1. However, when α3 > 1.0, λ2 < λ1 indicating
an exchange in the magnitude of the stability. For α3 > 1.0, it appears that the species B1
become more stable than B′1, indicating a transcritical-like bifurcation at α3 = 1.01. The
switching of stabilites is clear from the meaning of α3 which encompasses the ratio of the
forward to backward rate constants for this reaction and also contains the concentration of
the micelles which enhances the formation of the primed-species. The figure 2.3(b) shows
the rate of reformation of the species Bn and B
′
n which is seen to be a bit slower than the
monomeric species. The figure 2.3(a) shows a second switching at around α3 = 1.87 be-
yond which could be indicative of the effect of the strong nonlinearity of the system, which
needs to be experimentally verified. However, this could be a mathematical artifact and may
1We note that the traditional definition of trans-critical bifurcation involves a stable equilibrium and one
unstable equilibrium which exchange stabilities.
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Figure 2.3: The eigenvalues of matrix B as a function of α3. Case (a) shows the switching
event at a critical value of α3 while panel (b) shows the eigenvalues to the on- and off-
pathways.
point to the invalidity of α3 > 1.87. The latter case can be helpful in selecting appropriate,
physically meaningful rate constants which remains a significant confounding aspect of this
approach.
Next we varied the backward and forward parameters, αi, βi for i = 1, 2 (see figure 2.4).
When we increase the backward rates from our Base Case, the model exhibits an increase
in stability as represented by the magnitude of the eigenvalues (left image in figure 2.4).
Again, however, λ3 is a marginal case being just barely in negative territory. When we
increase forward rates (α2, β2) λ1 and λ2 become more negative while λ3 and λ4 become less
so (right image in figure 2.4). Thus, when backward and forward rates are more in line with
each other, the model exhibits greater stability.
The effect of n on the system was also explored (for 2 ≤ n ≤ 20) and seen to result in
some very significant changes to the stability of the system (see figure 2.5). In particular,
the eigenvalues λ1 and λ2 showed dramatic changes as n varies. As n increases, we see
an increase in the magnitude of stability of both λ1 and λ2, however, λ3 and λ4 exhibit a
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switching in stability as n increases, with n = 4 being the most stable environment for this
parameter, albeit marginally so. Both λ3 and λ4 are just barely in negative territory.
Overall, the stability of our model was very sensitive to the rate constants. The Base
Case model was seen to be asymptotically stable, but marginally so (λ3 and λ4). In other
words, perturbations to initial conditions decay but only gradually. At worst, when the
forward rates α2 and β2 are increased for instance, the model was neutrally stable. The
non-linearity of the system and the number of dimensions made analyzing the stability of
the system difficult. Perhaps the use of a non-linear method to analyze this problem in the
future may bear fruit.
2.4 Numerical Results
The system of equations (2.3)-(2.6) were solved using the Matlab ode45 function. A
sample solution is shown in Fig. 2.6 corresponding to initial conditions: B1(0) = 1, B
′
1(0) =
Bn(0) = B
′
n(0) = 0, α1 = β1 = .001, α2 = β2 = 1 and n = 4.
At equilibrium, equations (2.8)-(2.11) vanish, and (2.10) and (2.11) imply that,
α2B
n
1,e = α1Bn,e (2.22)
β2B
′n
1,e = β1B
′
n,e (2.23)
Substituting (2.22) and (2.23) into equations (2.8) and (2.9) we have α3B1,e = B
′
1,e. Thus,
if α3 = 1, we have B1,e = B
′
1,e, and using this in (2.22) and (2.23) means that Bn,e = B
′
n,e.
As can be seen from figure 2.6, at the limit it must be that we have
B∗n,e =
B∗n1,e
α1
= B∗1,e
where ∗ indicates both on- and off-pathway species. The high forward rates of the Base Case
strongly favor formation of n species, and as the model evolves it will seek equality of species
size in spite of the initial “head start” that both on- and off-pathway monomers have. At
α3 = 1 the system is such that B1,e = B
′
1,e = Bn,e = B
′
n,e, or the Nash equilibrium.
2.4.1 Nash Equilibrium
Figure 2.7 shows the time evolution of species for the Base Case for different values of α3.
The horizontal line α3 = 1 entirely determines on- or off-pathway species formation over the
long term for the Base Case. The yellow portion is where B1 < B
′
1 and Bn > B
′
n. For α3 > 1
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we do see dominance of Bn over B
′
n for a time, but over the long term, both off-pathway
species eventually dominate. The second figure shows the same graph, zoomed-in over the
time period t = 3000 − 4000. For α3 slightly above 1, we continue to see a thin band of
yellow, however at α3 = 1, over time we do have equality of all species. Interestingly, we
were unable to force B1 > B
′
1 and Bn < B
′
n, which would seem to be a result of not having
a direct pathway between B1 and B
′
n; a limitation of the model as constructed.
If viewed as a “competition” in the vernacular of Game Theory, who are the players,
what are the rules, and what are the payoffs? In the case of our model, the “players” are the
competing on- and off-pathways, the rules of the game are the reaction rate constants, and
the payoffs are the different equilibrium states. In the case of a competition with different
strategic options, the Nash equilibrium is the particular set of strategies that the players
would adopt regardless of how the competition behaved. In the biophysical context, it is the
set of parameters from which neither competing species would deviate if view as sentient
“competitors”. For our model, then the equilibrium Be|α3=1 = BNash,e is nothing but the
Nash equilibrium of the system given by
BNash,e :=
(
B1,e, B1,e,
α2
α1
Bn1,e,
β2
β1
Bn1,e
)
(see figure 2.6 for an example of such an equilibrium). This equilibrium exists only at α3 = 1
which has been seen to have special significance in terms of the stability of the system. It
follows that when α3 > 1, then the off-pathway species dominate creating more equilibrium
concentrations of B′1,e and B′n,e, and for α3 < 1, on-pathway dominates resulting in greater
production of B1,e and Bn,e.
We define k+ = k+1 L and k
− = k−1 so that the former leads to off-pathway and the
latter to on-pathway. The table below points to a sample case of the various strategies in
the competition between the two pathways with the pay-off for each “strategy” given by the
equilibrium concentrations.
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OFF-PATHWAY
k+ = 10 k+ = 1 k+ = 0.1
ON-
k− = 10 Equality on-pathway on-pathway
PATHWAY
k− = 1 off-pathway Equality on-pathway
k− = 0.1 off-pathway off-pathway Equality
Table 2.1: A sample game-theoretical payoff matrix to depict the on- and off-pathway com-
petition.
Figure 2.4: Eigenvalues as a function of backward rates (first frame) and forward rates
(second frame).
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Figure 2.5: Eigenvalues as n is varied.
Figure 2.6: Solution of Model with B1(0) = 1, B
′
1(0) = Bn(0) = B
′
n(0) = 0, α1 = β1 = .001,
α2 = β2 = 1 and n = 4.
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Figure 2.7: Time evolution of the Base Case model as α3 varies. The red region is strictly
on-pathway, blue is strictly off-pathway, and yellow is where B1 < B
′
1 and Bn > B
′
n or
mixed on-/off-pathway. Thus there are 2 possible equilibrium states, where a mixed state
can persist in the short run. The second graph is a zoomed-in version of the first, showing
the persistence of yellow over long periods of time for α3 close to 1.
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Chapter 3
Six Species Model
3.1 The Model
We wanted to increase the complexity of our system by increasing the number of species
to six. The idea behind increasing the model size was to add another pathway between
on- and off-pathway species. In this model, oligomers can react with the fatty acid L to
create off-pathway oligomers. The system of chemical reactions in our model consist of the
following,
A1 + L
k+1
k−1
A′1
n ·A1
k+2
k−2
An
n ·A′1
k+3
k−3
A′n
An + nL
k+4
k−4
A′n
m
n
·An
k+5
k−5
Am
m
n
·A′n
k+6
k−6
A′m
As with the 4 Species Model, the non-prime species, A1, An, and Am represent on-pathway
Aβ monomers and oligomers; whereas the prime species, A′1, A′n, and A′m, are the off-pathway
species which are created through a reaction with the fatty acid micelles, L. For each species,
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n = 4 and m = 20 unless otherwise specified; which denotes the order of oligomer.
Using the Law of Mass Action Kinetics, we formulate the system of differential equations
as follows.
dA1
dt
= nk−2 An − nk+2 An1 + k−1 A
′
1 − k+1 A1L (3.1)
dA
′
1
dt
= nk−3 A
′
n − nk+3 A
′n
1 + k
+
1 A1L− k−1 A
′
1 (3.2)
dAn
dt
= k+2 A
n
1 +
m
n
k−5 Am + k
−
4 A
′
n − k−2 An − k+4 AnLn −
m
n
k+5 A
m
n
n (3.3)
dA
′
n
dt
= k+3 A
′n
1 + k
+
4 AnL
n +
m
n
k−6 A
′
m − k−3 A
′
n −
m
n
k+6 A
′
n
m
n − k−4 A′n (3.4)
dAm
dt
= k+5 A
m
n
n − k−5 Am (3.5)
dA′m
dt
= k+6 A
′
n
m
n − k−6 A′m (3.6)
This system is then put into non-dimensional form. We let A0 be the characteristic concen-
tration of monomers and 1
k−1
be time, and define the dimensionless species as follows
B1 =
A1
A0
;Bn =
An
A0
;Bm =
Am
A0
;B
′
1 =
A
′
1
A0
;B
′
n =
A
′
n
A0
;B
′
m =
A
′
m
A0
The reaction constants are defined as follows:
α1 =
k−2
k−1
;α2 =
k+2 A
n−1
0
k−1
;α3 =
k+1 L
k−1
;α4 =
k+4 L
n
k−1
;α5 =
k−5
k−1
;α6 =
k+6 A
m
n −1
0
k−1
β1 =
k−3
k−1
;β2 =
k+3 A
n−1
0
k−1
;β3 =
k+5 A
m
n −1
0
k−1
;β4 =
k−4
k−1
;β5 =
k−6
k−1
Note that both α3 and α4 have a factor L which is responsible for off-pathway aggregation.
These will be the bridge variables between on- and off-pathway species in the analysis which
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follows. The dimensionless system is
dB1
ds
= nα1Bn − nα2Bn1 +B
′
1 − α3B1 (3.7)
dB
′
1
ds
= nβ1B
′
n − nβ2B
′n
1 + α3B1 −B
′
1 (3.8)
dBn
ds
= α2B
n
1 − α1Bn +
m
n
α5Bm + β4B
′
n − α4Bn −
m
n
β3B
m
n
n (3.9)
dB
′
n
ds
= β2B
′n
1 − β1B′n + α4Bn +
m
n
β5B
′
m −
m
n
α6B
′
n
m
n − β4B′n (3.10)
dBm
ds
= β3B
m
n
n − α5Bm (3.11)
dB′m
ds
= α6B
′
n
m
n − β5B′m (3.12)
Figure 3.1: Schematic of System with forward and backward rates.
Below is a table of the non-dimensional reaction variables that we will be referring to
in our work. Reaction variables between on- and off-pathway species will be referred to as
“bridge” variables.
On/Off Pathway Reaction Rate Variables
Forward Backward
On-Pathway α2 β3 α1 α5
Off-Pathway β2 α6 β1 β5
Bridge α3 α4 β4
Table 3.1: Table of reaction rates between species
Throughout this part of our work, we will primarily be analyzing two models which will
be referred to as the Base Model and Model 2. Our choices of the parameters in these two
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models are guided by prior work with our collaborators in the belief that they capture the
essential dynamics of the system, without loss of generality. In our Base Model, we set
all forward rates and bridge rates equal to 1 and all backward rates to .001, as previous
mathematical models and experimental data have indicated [43]. In the context of our
model, a forward rate is defined as one that converts a smaller molecular structure into a
larger structure, and backward being the reverse process. In Model 2, we set all forward and
backward rates equal. We used Matlab’s ode 45 for our numerical solutions.
3.2 Equilibrium Points
In order to study the stability of the system we have had to rely on experimental data
to determine our rate constants which in turn determine our equilibrium, or fixed point,
concentration levels [43]. With the Four Species Model, we were able to analytically solve
for the equilibrium concentration sizes by simultaneously solving the system of ODEs in
terms of a single species. Because the Six Species model is so highly interdependent, we
were unable to use this approach. The presence of two bridge reactions between on- and off-
pathway meant that each species was dependent on two other species in a circular fashion.
Given the above discussion, our first problem was how to determine the equilibrium points
for the system, with the stipulation that all species sizes be greater than zero. Equilibria
where any species size is zero would be of little interest in the context of our problem.
Because our system is non-linear and 6 dimensional, there are many possible fixed points.
We weren’t interested in classifying all of these points, but only those corresponding to our
models.
In general, equilibrium for our model is the set of points that would make (3.7)-(3.12)
vanish for a given set of parameter values. We knew from the numerical solutions of the
model that the system appeared to settle at equilibrium, or more accurately, that each
species exhibited asymptotic behavior. In the absence of being able to solve our system, we
wanted to approximate a limiting value for each species. The non-analytical analog of this
would be where the change in concentration size for each species gets reasonably close to
zero as t → ∞, knowing that absolute zero would most likely be unachievable due in part
to numerical error. One solution to this problem would be to just use very large values of t
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and take the ending concentration levels as our equilibrium points. The necessity of running
a large number of simulations under different rate environments, however, meant that we
needed to limit how big t could be.
To solve the problem of having to limit computation time, we ran both models through a
code that would identify the time T when the change in all species sizes was less than 0.1%
of the previous level using time increments of 5. For instance, we computed the change in
concentrations sizes for t = 0 : 5, t = 0 : 10, etc. This would be a proxy for solving our system
for 0, and the concentration levels at time T would be our equilibrium concentration sizes.
As it turns out, concentration sizes continue to fluctuate over time for both models, but in all
cases these fluctuations were within 0.1% of previous levels for t > T , which we considered
acceptable. To confirm our equilibrium values, we ran the results through Matlab’s fsolve as
will be discussed shortly. In the following simulations we set initial conditions to be B1 = 1
with all other species at 0. Below are the graphs of the numerical solutions of the Base
Model and Model 2.
As can be seen from the graphs in figure 3.2, as time increases the concentration levels
exhibit asymptotic behavior and equilibrium appears to be achieved. We found, however,
that the “look” of the graph was deceptive. Because the absolute size of the concentration
of Bm and B
′
m were so small, the fluctuations weren’t showing up on the solution graphs.
Figure 3.3 shows graphs of the Base Model and Model 2 showing the percentage change in
concentration sizes as a function of time using representative species. Bm is shown as that
is one of the species that tended to have greater fluctuations over time.
It’s clear from 3.3 that there continues to be relatively large percent changes in concen-
tration levels in the Base Model while the concentration levels in Model 2 “settle” down more
quickly. As our working definition of equilibrium, we therefore wanted to see the absolute
percentage change in concentration of any species to be no greater than 0.1% over a period
of 5 units of time. As it turned out, in order to achieve our definition of equilibrium for the
Base model, we needed to use a time span of t = 0 : 2200, whereas for Model 2 we needed a
time span of just t = 0 : 20. We had therefore found that the type of rate regime used has
a dramatic effect on the time it takes for the system to reach equilibrium. Figure 3.4 is a
graph of the Base Case model with t = 0 : 2200, and a zoomed in concentration size window.
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Figure 3.2: Solutions of the Base Model and Model 2.
While it appears that it takes longer for B1, B
′
1, Bn, and B
′
n to settle, it is in fact Bm
and B′m (in green) that continue to grow until our definition of equilibrium is achieved at
t = 2200. To confirm our hypothesis, we ran the model through Matlab’s numerical non-
linear system solver, fsolve. As our initial “guess”, we used the final concentration size at
t = 2200 and with just 1 iteration, fsolve returned an equilibrium value for each species
that was within 2% of our guess. By increasing the time span to 2500, we were able to get
this difference under 1%. We considered these to be reasonably accurate equilibrium values
for our Base Case model with which to work. Below are plots of the percentage change of
B1 and B
′
m over different timespans. B
′
m continues to grow slowly as B1 fluctuates over
t = 350 − 450. In the second plot, B′m is approximately at 0% change while B1 continues
fluctuating.
Under the Model 2 regime shown below, equilibrium is achieved more quickly. Using a
time span of just t = 0 : 20, and taking the ending concentration sizes as an initial guess,
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Figure 3.3: Absolute percentage change of the concentration of B1 and Bm as a function of
time over identical time spans. Model 2 achieves equilibrium more quickly.
fsolve returned a value that was at worst, 0.08% different from our equilibrium value. The
difference in time it takes to achieve equilibrium seems to be a function of the ratio of
backward to forward rates: the closer that ratio is to 1, the more quickly the system reaches
equilibrium. We ran a power regression of the data and found that the time to equilibrium
is TE ≈ 25r−.615 (figure 3.6 and table) where r is the ratio of backward to forward rates.
Intuitively speaking, the direction that has a much smaller reaction rate will tend to become
overwhelmed until that species has a critical concentration mass where, despite the lower
reaction rate, it’s greater relative concentration size will “push back”. This will create a
cycle of over-shoot that will take longer to dissipate. Interestingly, in the case of Model 2
as our definition of equilibrium is achieved it is B′m that has the greater fluctuations while
B1 is more stable (see figure 3.7), the opposite of the Base Model. It would appear that
increasing backward rates, while enabling the model to settle to equilibrium more quickly
30
Aβ Protein Aggregation
Figure 3.4: Solution of the System (Base Case) with t = 0 : 2200 and zoomed in concentration
size. Note the slow but continued growth of Bm and B
′
m.
Figure 3.5: Plots showing percentage change of B1 and B
′
m over different timespans for the
Base Model.
does increase fluctuations in the concentration size of n and m species relative to monomers.
As increasing backward rates from the Base Model to Model 2 had greatly reduced the
time it took to achieve equilibrium, it made sense to look at a regime where backward
rates are greater than forward rates. While not necessarily physically meaningful in the
context of our problem, for comparisons sake, we wanted to know the time horizon over
which equilibrium was achieved. For this model, we first set forward rates to be 0.01, and
then 0.001, with backward rates equal to 1 in both cases. In this scenario, the model did not
settle down to our definition of equilibrium even over a time span of t = 0 : 5000. In fact,
large (percentage-wise) fluctuations in the concentration of B′m became greater over time.
Figure 3.8 is the graph of this simulation. Note that the scale of the graph is ±150%.
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Time to Equilibrium
Backward/Forward Ratio Equilibrium Time
0.0001 5,190
0.001 2,200
0.01 595
0.1 105
1 20
Table 3.2: Time to equilibrium as a function of the ratio of backward to forward rates.
Figure 3.6: Equilibrium time as a function of the ratio of backward to forward rates.
Due to low forward rates, the concentration size of B1 stays high and stable throughout,
but there are periodic, large percentage changes in the size of B′m. We analyzed the concen-
tration pattern of both B1 and B
′
m over this period and their growth and decline patterns
are a mirror image of each other: periods of increase in B1 were accompanied by declines in
B′m. Because the relative concentration sizes are so different, percentage-wise changes in B1
were on a much smaller scale, as can be seen from the graph.
From our equilibrium analysis of these three models we found when the ratio of backward
to forward rates is close to 1, the model settles at equilibrium more quickly than when there
are large differences in the magnitude of backward and forward rates. Also, the higher we
put backward rates the more volatility in the concentration size of n and m species relative
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Figure 3.7: Fluctuations in the size of B1 and B
′
m under Model 2 conditions, after equilibrium
is achieved.
to monomers, whereas higher forward rates had the opposite effect.
Below is a table of the analysis of equilibrium.
Analysis of Equilibrium
Base Model Model 2 High Backward
Time T to Equilibrium T = 2200 T = 20 -
Max. Difference Model/fsolve 1.7% 0.08% -
Table 3.3: Time to equilibrium of the Base Model and Model 2 versus fsolve.
We also looked at both models with various sizes of oligomers by varying n and m. In
both cases, increasing n and m had the effect of increasing the time it took for each model
to reach equilibrium. Below is a table of results. It could be that the higher the power of the
non-linear terms, the greater the potential for over- and under-shoot as the model evolves
over time, thus taking longer to achieve equilibrium.
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Figure 3.8: Percentage change in concentration of B1 and B’m with high backward rates.
Time to Equilibrium
Oligomer Size Base Model Model 2
n = 2,m = 10 780 25
n = 4,m = 20 2,200 20
n = 6,m = 30 3,650 30
n = 8,m = 40 4,020 35
Table 3.4: Table of time to equilibrium values as n and m are varied.
3.3 Linear Stability Analysis
Like the 4 species model, we linearize the dimensionless system as shown below.
B1 = B1,e + X1 (3.13)
B′1 = B
′
1,e + Y1 (3.14)
Bn = Bn,e + Xn (3.15)
B′n = B
′
n,e + Yn (3.16)
Bm = Bm,e + Xm (3.17)
B′m = B
′
m,e + Ym (3.18)
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Here, for instance, B1,e is the equilibrium concentration of the species B1, and X1 is the
perturbation. For our equilibrium concentrations, we used the values derived in the previous
section.
We substitute these values into equations (3.7)-(3.12) and keep only the linear terms of
order . The linearized system is
dX1
ds
= nα1Xn − n2α2Bn−11,e X1 + Y1 − α3X1 (3.19)
dY1
ds
= nβ1Yn − n2β2B′1,eY1 + α3X1 − Y1 (3.20)
dXn
ds
= nα2B
n−1
1,e X1 − α1Xn +
m
n
α5Xm + β4Yn − α4nXn − (m
n
)2β3B
m
n
−1
n,e xn (3.21)
dYn
ds
= β2B
′n−1
1,e − β1Yn + nα4Xn +
m
n
β5Ym − (m
n
)2α6B
′
n,e
m
n
−1Yn − β4Yn (3.22)
dXm
ds
=
m
n
β3B
m
n
−1
n,e Xn − α5Xm (3.23)
dYm
ds
=
m
n
α6B
′
n,e
m
n
−1Yn − β5Ym (3.24)
Which is then put into operator matrix form using the appropriate rate constants and equi-
librium values found in the previous section
B =
⎛
⎜⎜⎜⎜⎜⎜⎜⎜⎝
−(n2α2Bn−11,e + α3) 1 nα1 0 0 0
α3 −(n2β2Bn−11,e + 1) 0 nβ1 0 0
nα2B
n−1
1,e 0 −(α1 + α4 + mn 2β3B
m
n
−1
n,e ) β4
m
n
α5 0
0 nβ2B
′n−1
1,e α4 −(β1 + mn 2α6B
′m
n
−1
n,e + β4) 0
m
n
β5
0 0 m
n
β3B
m
n
−1
n,e 0 −α5 0
0 0 0 m
n
α6B
′m
n
−1
n,e 0 −β5
⎞
⎟⎟⎟⎟⎟⎟⎟⎟⎠
We then compute the eigenvalues of B, the Jacobian, which is shown in the table below.
Because we were not able to determine equilibrium for the high backward rate regime, we
have excluded it from the stability analysis. Notice that all of the eigenvalues are negative
with the exception of λ5 = 0 for the Base Model and λ2 = 0 for Model 2.
Eigenvalues of Base Model and Model 2
λ1 λ2 λ3 λ4 λ5 λ6
Base Model −2.0320 -2.0020 -0.0320 -0.0028 0.0000 -0.0009
Model 2 −4.0149 0.0000 −2.0149 −2.0000 −1.0000 −0.9999
Table 3.5: Eigenvalues of the Base Model and Model 2.
Below are plots of the Base Model λ5 as a function of both α3 and α4.
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Figure 3.9: The first figure is λ5 as a function of α3 and the second graph is λ5 as a function
of α4. Note that the scale is 10
−16.
λ5 is zero out to the 15th decimal place. In the case of Model 2, λ2 was on a similar
scale. λ5 is fluctuating between ±2.5× 10−16, depending on parameter values, or effectively
zero if we make allowance for round-off error in the numerics. This would mean that neither
model is asymptotically stable, but rather neutrally stable. While perturbations of initial
conditions won’t blow up, nor will they decay to equilibrium.
As the rate regime had a significant impact on time to equilibrium, so too did it impact
stability. We therefore ran simulations of each model while varying the rate regime. Of key
interest was the effect of the bridge parameters, α3 and α4, and their effect on the stability
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Figure 3.10: λi as a function of α3 and α4.
of each model. Figures 3.10 and 3.11 are contour plots of the eigenvalues of the Base Model
and Model 2 with 0 ≤ α3, α4 ≤ 2. We incremented the two parameters by 0.1.
The stability picture of each system is significantly different. In the Base Model, λ5 is
zero for all values of α3 and α4, while for Model 2, there was some switching between λ2
and λ4, as seen in the upper left hand corner of the contour plots for these two eigenvalues
in figure 3.11.
We ran simulations for other reaction rate regimes and found that over a range of values
for α3 and α4, there was consistent switching of eigenvalues. Figure 3.12 shows Model 2 with
forward rates doubled. Note the switching behavior between λ2, λ3, and λ4.
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Figure 3.11: λi as a function of α3 and α4.
Figure 3.12: Switching Behavior of λ2, λ3 and λ4 with forward rates doubled.
Figure 3.12 is a good example of the switching behavior we observed as we varied reaction
rates. Note how λ3 = 0 for low α3, α4, and that as we increase these two parameters, λ2 is
zero and then finally λ4 is zero. This was the case for all rate environments that we ran,
albeit not always as pronounced. Thus, for any rate environment, the stability of the system
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near the point of equilibrium was neutrally stable.
We then ran contour plots varying n and m which are shown below. We ran two cases for
each model: n = 2, m = 4, and n = 8, m = 40. These would represent oligomer sizes both
less than and greater than our standard designation for n and m of 4 and 20 respectively.
Figure 3.13: Switching of eigenvalues in Base Model as n and m are varied. The white region
in both plots indicates a zero value for the eigenvalue for any value of the parameters.
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Figure 3.14: Switching of eigenvalues in Model 2 as n and m are varied.
In the case of the Base Model, there was no switching of eigenvalues for a given species
size environment as α3 and α4 are varied. For the Base Model, λ5 is zero for all values of
α3 and α4 when n = 2 and m = 4, and when n = 8 and m = 40, λ4 is zero. For Model
2, there is switching between λ2, λ3, and λ4 when n = 2 and m = 4, whereas when n = 8
and m = 40, there is switching between λ1, λ2 and λ3. In general, as with the Four Species
Model, as n and m are increased, the overall magnitude of stability increases.
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Switch Cross
α4 α3 α3
2 0.9 2
4 1.525 4
8 2.35 8
16 4.05 16
32 6.65 32
64 8.05 64
Table 3.6: Switch and cross points of α3 as a function of α4.
Finally, we then looked to analyze the effect on λ1 and λ2 of varying the bridge variables
α3 and α4. We observed a pattern of switching and crossing of the eigenvalues as the two
bridge parameters are varied. Below is a graph of where we have set α4 = 2 and 0 ≤ α3 ≤ 4.
Note the switching at α4 = 2 and α3 ≈ 0.9 and crossing at α3 = α4 = 2. The table below
shows switching and crossing points for λ1 and λ2 as α3 and α4 vary.
Figure 3.15: Switching and crossing of λ1, λ2 as a function of α3.
As can be seen, there is crossing where α3 = α4, whereas switching has an exponential
relationship between the two parameters. We ran a regression model of the data and found
that α4 ≈ 2.04× 1.55α3 modeled the switch points with a r2 = 0.953.
We have found that varying reaction rates and oligomer size affected the stability of
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the model. As with the 4 Species Model, given the non-linear nature and the number of
dimensions, analyzing the stability of the model has proved difficult. We were unable to
employ standard methods such as using phase plots and determining bifurcation points that
are used with two dimensional models. Perhaps our analysis of equilibrium, which has shown
that certain rate regimes result in the model not being able to reach equilibrium, explains the
borderline nature of the stability of the model. Using just linear stability analysis, however,
we have shown that over a range of parameter values the model is neutrally stable.
3.4 Numerical Results
The key parameters in our model are α3 and α4 as they are the bridge variables governing
the reaction between on- and off-pathway. We therefore wanted to see the effect of varying
both on species formation while holding all other reaction rates constant. Figure 3.16 shows
the species concentrations as a function of time for the Base Model. For the purposes
of this topic, we are showing a shorter time span, our previous discussion of equilibrium
notwithstanding: the essential look of the graph to the naked eye is indistinguishable.
Figure 3.16: Concentration levels of Base Model.
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Figure 3.17: Concentration levels of Base Model with α3, α4 =10.
The first graph in figure 3.16 shows the solution of the system for the Base Model, and
the second shows the solution of the model with increased α3 and α4. Under the Base Model
reaction rate regime, the prime and non-prime species are approximately equal, whereas
when we increase the bridge variables we see an outperformance of all prime species as
would be expected.
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Figure 3.18: Concentration of B
′
1 and B
′
n as α3 and α4 are varied.
Figure 3.18 shows the solution with just B′1 and B′n as we vary α3 and α4. Note that as
we increase both α3 and α4, we get an initial spike in the concentration of B
′
1 before settling
back to equilibrium, whereas B
′
n exhibited no such initial spike. This reflects the fact that
over time, the concentration of B
′
1 is reduced in the forward reaction B
′
1 ⇀ B
′
n. Figure 3.19
shows just this part of the system.
Figure 3.19: Progression of Species Concentrations. Over time, the spike in concentration
of B
′
1 is reduced as monomers of that species aggregate into B
′
n.
We now look at the relationship between α3 and α4, the bridge rates, and the ratio of
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off-pathway to on-pathway species concentrations. When we increase both α3 and α4, we see
a direct increase in the ratio of off-pathway species to on-pathway species. The relationship
is linear and can be written as: B′1/B1 = α3, and B′n/Bn = α4. Because B′m/Bm is not
directly governed by the bridge variables, it is slower to react to an increase, but eventually
exhibits what appears to be exponential or power growth at higher values of the bridge
variables. This is most likely due to the fact that B′m formation is dependent upon α3 and
α4, so that increasing both eventually impacts B
′
m in a greater manner.
Figures 3.20 and 3.21 underscore the importance of the bridge variables. If we leave α4
unchanged and just increase α3, there is limited flow through from B
′
1 to B
′
n and B
′
m: their
ratios to the non-prime species increase slightly above 1, but cease to grow from there even as
α3 continues to increase. Therefore, the bridge reaction Bn  B′n is critical in the formation
of n and m species. For our model, oligomer to oligomer reactions are more significant than
monomer to monomer in terms of overall aggregation.
Figure 3.20: Concentration ratios as λ3 and λ4 vary.
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Figure 3.21: Concentration ratios as λ3 varies, with λ4 held constant.
We then wanted to test the model to make sure that we could force any species to outper-
form by varying the rate constants. Forcing B1 to outperform, for instance, is just a matter
of greatly reducing or shutting off all the forward reactions, and therefore easily done. For
species further down the reaction “chain”, we are required to increase forward reactions to
get the desired outperformance. In the case of B
′
m, we were able to get outperformance of
this species in absolute terms by dramatically increasing the forward reaction rates α3, β2,
and α6 (see figure 3.22). Putting these reaction rates at 5×104 we were able to achieve this.
Outperformance by Bm was achieved in a similar manner. Doing this has little physical
relevance, but does demonstrate the ability of the model to force a particular species to
outperform in absolute terms.
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Figure 3.22: By increasing the forward reaction rates in the direction of B
′
m, we were able
to get B
′
m to outperform all other species on an absolute basis.
3.4.1 Nash Equilibrium of the Six Species Model
As with the Four Species Model, we wanted to look at our model from a game theoretic
point of view. Below are schematics of the 4 equilibrium states that our model can achieve.
Figure 3.23: The four equilibrium states of the system. Clockwise from top left, the first
figure has all on-pathway species outperforming off-pathway. The second figure has all
off-pathway species outperforming on-pathway, and the remaining two are mixed on-/off-
pathway.
From top-left, clockwise, the first schematic highlighted in red is strictly on-pathway,
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with non-prime species “winning”. The next highlighted in blue is strictly off-pathway, with
all prime species winning. Yellow and green are a mixture of on/off-pathway.
Using our Base Model reaction rates, we ran simulations varying α3 and α4 to determine
what values of those parameters would cause the different configurations of species domi-
nance. For the simulation below we varied α3 and α4 between 0 and 2 in increments of .02
which resulted in 10,000 discrete points. Figure 3.25 has 0 ≤ α3, α4 ≤ 10.
Figure 3.24: Aggregation pathways as a function of α3 and α4 with step size of .02. Colors
correspond to the equilibrium states from Figure 3.22.
Figure 3.25: Aggregation pathways as a function of α3 and α4. The blue region continues
to “win” as α3 and α4 increase without limit.
For the Base Model, the point (α3, α4) = (1, 1) is critical. At (1, 1), the concentration
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Payoff Matrix
α3 < 1 α3 = 1 α3 > 1
α4 < 1 On Mixed Mixed
α4 = 1 Mixed On=Off Mixed
α4 > 1 Mixed Mixed Off
Table 3.7: Table of equilibrium states as a function of α3 and α4.
of on- and off-pathway species are equal. As we vary α3 and α4 from this point we begin
to see dominance of one species type over another. Notable too is the fact that the bound-
aries between the different equilibrium states are so linear: the line α4 = 1 determines the
switching between on- and off-pathway dominance of n and m species, and the line α3 = 1
determines the switching between on- and off-pathway dominance of monomers.
Table 3.7 shows the equilibrium states as a function of α3 and α4 in the form of a payoff
matrix. The Nash Equilibrium, in boldface, is where on-pathway species concentrations are
equal to off-pathway species concentrations.
Next, we prove that the point α3 = α4 = 1 is the Nash Equilibrium of both the Base
Model and Model 2.
Theorem 1. The Nash Equilibrium of the Base Model and Model 2 occur at the point
α3 = α4 = 1.
Proof. In both the Base Model and Model 2, we set all non-bridge forward rates equal to
each other, and all backward rates equal to each other. We let δ be forward rates and μ be
backward rates, and assume that the system is in equilibrium. We then simultaneously solve
equations (3.7)-(3.12) for zero. Equations (3.11) and (3.12) can be rewritten as
δB
m
n
n = μBm (3.25)
δB′n
m
n = μB′m (3.26)
Substituting these expressions into equations (3.09) and (3.10) and then simplifying, we
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rewrite the original system (3.7)-(3.12) as
nμBn +B
′
1 − nδBn1 − α3B1 = 0 (3.27)
nμB
′
n + α3B1 − nδB
′n
1 −B
′
1 = 0 (3.28)
δBn1 + δB
′
n − μBn − α4Bn = 0 (3.29)
δB
′n
1 + α4Bn − μB′n − δB′n = 0 (3.30)
δB
m
n
n − μBm = 0 (3.31)
δB′n
m
n − μB′m = 0 (3.32)
We then solve (3.27) and (3.28) for B′1 and find that
δBn1 − μBn = μB′n − δB
′n
1 (3.33)
Let δBn1 − μBn = μB′n − δB
′n
1 = γ. If γ = 0, equations (3.27)/(3.28) simplify to α3B1 =
B′1 and α4Bn = B′n, and therefore equality of off-pathway and on-pathway species when
α3 = α4 = 1. Assume, on the contrary, that γ = 0, and that w.l.og., γ > 0. If we let
α3 = α4 = δ = 1, this implies that
B′1 = B1 + nγ (3.34)
Bn = B
′
n + γ (3.35)
which means that B′1 > B1 and Bn > B′n. But γ > 0 and equation (3.33) mean that
δ
μB
n
1 > Bn and B
′
n >
δ
μB
′n
1 , which by transitivity further implies that B
n
1 > B
′n
1 . This,
however, contradicts our earlier assertion that B′1 > B1. Thus, γ = 0, and when α3 = α4 = 1,
both models are at Nash Equilibrium with the concentration of off-pathway species equal to
on-pathway species.
It’s notable that unlike with the Four Species Model, we do not get equality of all species
types with one another at the point α3 = α4 = 1. There is undoubtedly at least one unique
set of parameters that would get equality of all 6 species, but finding that would be difficult
to say the least. As shown with forcing the outperformance of B′m, we would need to increase
forward rates dramatically to get equality of species.
We then ran the same code for Model 2, which is the graph below.
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Figure 3.26: Aggregation pathways as a function of α3 and α4 with backward and forward
rates equal.
Once again, the point (α3, α4) = (1, 1) is critical, however, unlike with the Base Model
case it doesn’t strictly define outperformance of B1 over B
′
1 and vice versa: we still see
B1 outperform B
′
1 for α3 > 1 and low α4, and B
′
1 outperform B1 for α3 < 1 and high
α4. The major difference is that the Red and Blue regions (strictly on-pathway and strictly
off-pathway respectively) increase at the expense of Green and Yellow (Mixed). More impor-
tantly, the range of points (α3, α4) over which on-pathway wins, gets bigger when backward
rates are at parity with forward rates. For 0 ≤ α3 < 1, by increasing β1 and β5 we are
effectively shutting off the B1 ⇀ B
′
1 bridge towards off-pathway aggregation, hence the in-
crease in red in the upper left of the graph in 3.26. The reverse happens in the lower right
for 0 ≤ α4 < 1 as we get greater off-pathway aggregation up to a point. Despite increasing
α3 above 2, however, if we reduce α4 we continue to see a thin band of dominance (see Fig.
3.27) of Bn and Bm over their primes. Once again, this shows that the Bn ⇀ B
′
n bridge
is more critical for off-pathway aggregation of n and m species than B1 ⇀ B
′
1. Figure 3.27
shows the lower right corner of 3.26 with higher values of α3, showing that if we reduce α4
we still get on-pathway dominance of n and m species even for high α3. Thus, it is difficult
to force off-pathway aggregation of n and m species by just forcing over the B1 ⇀ B
′
1 bridge.
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Figure 3.27: Dominance of on-pathway n and m species for low α4 and high α3.
Figure 3.28: Species formation by iteration when successively adding one unit of B1 at
each iteration. Note that with the exception of Bm and B
′
m in the Base Model, prime and
non-prime species are right on top of eachother.
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Lastly, we wanted to look at our model in a more dynamic way. We decided to continu-
ously add new B1 to the system and then watch how each model evolved (figure 3.28). For
both models, the amount of on-pathway and off-pathway species was virtually equal (for the
Base Model, Bm does outperform B
′
m). Also, the amount of Bm and B
′
m eventually outstrips
all other species, followed by the n species. In the case of Model 2, the outperformance of the
m species takes longer to happen, which is the result of backward rates being much higher
than those for the Base Model. It seems that both models favor the formation of oligomers
over monomers.
3.5 Fluxes and Forces
Based on the system of equations corresponding to the 6-species aggregation model, we
can compute certain thermodynamic quantities such as fluxes, forces and entropy production
for the different pathways that we have identified. The pathways (Pi, i = 1, 2, 3, 4) are
equations 3.36-3.39, where P
(−)
42 refers to the reverse of P42. The fluxes corresponding to
these pathways is given by Ji = R
f
i − Rbi (i = 1, 2, 3, 4) where Rf refers to the forward
reaction flux and Rb is the backward reaction flux. As a result the individual fluxes are
given by equations 3.40-3.43.
Figure 3.29: A schematic of the reaction pathways.
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On-Pathway P1 = P11 ∪ P12 (3.36)
Off-Pathway P2 = P21 ∪ P22 ∪ P23 (3.37)
Off/On-Pathway P3 = P31 ∪ P32 ∪ P33 ∪ P34 = P21 ∪ P22 ∪ P (−)42 ∪ P12 (3.38)
On/Off-Pathway P4 = P41 ∪ P42 ∪ P43 = P11 ∪ P42 ∪ P23 (3.39)
J1 = J11 + J12
= (α2B
n
1 − α1Bn) +
(
β3B
m/n
n − α5Bm
)
(3.40)
J2 = J21 + J22 + J23
=
(
α3B1 −B′1
)
+
(
β2B
′n
1 − β1B′n
)
+
(
β6B
′m/n
n − β5B′m
)
(3.41)
J3 = J31 + J32 + J33 + J34 = J21 + J22 − J42 + J12
=
(
α3B1 −B′1
)
+
(
β2B
′n
1 − β1B′n
)
+
(
β4B
′
n − α4Bn
)
+
(
β3B
m/n
n − α5Bm
)
(3.42)
J4 = J41 + J42 + J43 = J11 + J42 + J23
= (α2B
n
1 − α1Bn) +
(
α4Bn − β4B′n
)
+
(
β6B
′m/n
n − β5B′m
)
(3.43)
Similarly, the forces corresponding to the different pathways can be given by the reaction
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affinities or forces which can be given by the expression Fi = RT ln
(
Rfi
Rbi
)
.
F1 = F11 + F12 = RT ln
(
α2B
n
1
α1Bn
)
+RT ln
(
β3B
m/n
n
α5Bm
)
= RT ln
(
α2β3B
n
1B
m/n
n
α1α5BnBm
)
(3.44)
F2 = F21 + F22 + F23 = RT ln
(
α3B1
B′1
)
+ ln
(
β2B
′n
1
β1B′n
)
+ ln
(
β6B
′m/n
n
β5B′m
)
= RT ln
(
α3β2β6B1B
′n
1 B
′m/n
n
β1β5B′1B′nB′m
)
(3.45)
F3 = F31 + F32 + F33 + F34 = F21 + F22 − F42 + F12
= RT ln
(
α3B1
B′1
)
+RT ln
(
β2B
′n
1
β1B′n
)
−RT ln
(
α4Bn
β4B′n
)
+RT ln
(
β3B
m/n
n
α5Bm
)
= RT ln
(
α3β2β3β4α4B1B
′n
1 B
m/n
n
β1α4α5B′1BnBm
)
(3.46)
F4 = F41 + F42 + F43 = F11 + F42 + F23
= RT ln
(
α2B
n
1
α1Bn
)
+RT ln
(
α4Bn
β4B′n
)
+ ln
(
β6B
′m/n
n
β5B′m
)
= RT ln
(
α2α4β6B
n
1B
′m/n
n
α1β4β5B′nB′m
)
(3.47)
The reaction affinities are related to the Gibbs free energy of the system by
−ΔGi = Fi = RT lnKeq (3.48)
where Keq is the equilibrium constant for the reaction. The Gibbs energy function is also
related to the entropy, S, in the system by
ΔGi = −TΔS (3.49)
Therefore, if the change in ΔG is negative (i.e. change in entropy is positive), then the
chemical reaction occurs spontaneously at constant pressure and temperature.
3.6 Entropy Production
The entropy production corresponding to the various pathways is given by
σi =
1
T
∑
k
FikJik (3.50)
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where i = 1, 2, 3, 4. Expanding this sum yields:
σ1 =
1
T
(F11J11 + F12J12) (3.51)
σ2 =
1
T
(F21J21 + F22J22 + F23J23) (3.52)
σ3 =
1
T
(F31J31 + F32J32 + F33J33 + F34J43) (3.53)
σ4 =
1
T
(F41J41 + F42J42 + F43J43) (3.54)
where each of the component terms can be obtained from the expressions above. We think
that computing the entropy production rate for each of the pathways can reveal significant
information about the underlying energetics of the different pathways. To begin with, we
first compute the values of σis at the equilibrium concentrations of the oligomers. The results
are presented in the form of contour plots of σi as a function of the order parameters α3 and
α4.
Figure 3.30: A contour plot of entropy production along the four different pathways as a
function of α3 and α4. The red regions correspond to large values, while blue points to
smaller values of entropy production. For this calculation, the forward rate constants along
the purely on and off pathways are taken to be equal to 1.0 while he backward constants are
0.001.
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Conclusions
4.1 Four Species Model
An important consideration in any numerical simulation such as ours is error. Because
we are dealing with a relatively large, non-linear system it was necessary to use numerical
methods for our solutions. Our choice of numerical solution method was ode45 in Matlab,
which is the Runge-Kutta method of order 4/5. ode45 is considered the method of choice
for non-stiff systems of equations. Stiff equations occur when the solution has a transient
exponential. When this happens, the error term, as represented by the nth derivative, can
get very large in relation to the solution itself [46]. Determining whether a system is stiff in
Matlab is a matter of running the code through ode 45 and seeing if it returns a solution.
If it does, the problem is non-stiff, and if it doesn’t, or run times are exceedingly long, the
problem could potentially be stiff. Our system did not encounter this problem. Nonetheless,
any method employed will involve truncation error. The Runge-Kutta Method of order 4
has local truncation error of O(h4). Thus, error related to numerical methods is impossible
to avoid for problems such as ours, and so must be taken into account when considering
whether a model accurately represents the behavior of a physical system. Our limitation
with respect to comparing our results with empirical data makes this an enduring problem
in the study of modeling Aβ aggregation.
Our linear stability analysis of the model showed that the system is stable for a broad
range of parameters. For the Base Case, all eigenvalues were negative indicating asymptotic
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stability. Increasing backward rates relative to forward rates increased the magnitude of
stability as represented by the eigenvalues. λi for i = 1, 2, 3, 4 all became more negative
as backward rates were increased relative to forward rates. We had mixed results when
we increased forward rates. λ1 and λ2 become more negative, but λ3 and λ4 become less
negative. The system is still asymptotically stable, but marginally less so. Varying n also
had mixed results. All eigenvalues become more negative except λ3 which becomes less
negative.
In conclusion, our analysis of linear stability determined that the model was asymp-
totically stable, with some variation in the magnitude of stability depending on parameter
values.
Equilibrium analysis also revealed some interesting results. The parameter α3 determines
switching between on- and off-pathway species formation, given that it contains the fatty acid
micelle term L. For α3 < 1 formation of on-pathway species exceeds that of off-pathway
species, with α3 > 1 leading to an outperformance of off-pathway species formation. At
α3 = 1, the system is at the Nash Equilibrium where we will have equality of all species over
the long term. While α3 = 1 is the line of demarcation between on- and off-pathway species
formation, for α3 > 1 we did still see outperformance of Bn over B
′
n for a period of time. As
α3 approaches 1 from the right, this phenomenon persists for increasingly longer periods of
time. Eventually, however, the concentration of B′n exceeds that of Bn. We were unable to
force a situation where B1 > B
′
1 and Bn < B
′
n. This is most likely due to the fact that Bn
has a direct reaction with B1 whereas B
′
m is one step removed.
4.2 Six Species Model
Unlike with the Four Species model, we were unable to analytically solve for equilibrium.
We therefore had to use our numerical solutions in determining equilibrium, which were then
verified with Matlab’s fsolve and found to be within 1% of our values. We found that the time
the system took to achieve equilibrium was very dependent upon the reaction rate regime.
When the ratio of forward to backward rates is close to 1, our model achieves equilibrium
very quickly. When forward rates are considerably higher than backward rates, or vice versa,
the system takes longer to achieve equilibrium due to a cycle of over-shooting of species sizes
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resulting from a large difference in reaction rates. In the case of high backward rates, the
model didn’t achieve equilibrium at all. Thus, Model 2 achieved equilibrium over a much
shorter time span than the Base Model. The inability of the model to achieve equilibrium
under the conditions of high backward rates is no more than a curiosity as high backward
rates would indicate no aggregation. Increasing n and m resulted in the model taking longer
to achieve equilibrium, which seems to mean that higher exponents increase fluctuations in
the model before it is able to settle down.
In terms of stability, both of the 6 species models we experimented with were neutrally
stable. For all sets of parameter values, there was consistently one eigenvalue with zero real
part, indicating neutral stability: neither do perturbations die out over time nor do they
blow up. This was in contrast to the Four Species model which is asymptotically stable over
a broad range of parameter values. This is possibly a result of the greater complexity of the
Six Species model and the addition of a higher degree oligomer size, m. Further study of
the problem using non-linear methods would be the next step in analyzing stability.
We varied α3 and α4 between 0− 2, and while we saw switching of stabilities, there was
always at least one eigenvalue with zero real part. Doubled forward rates and varying n and
m saw the same phenomenon: switching of eigenvalues, but neutral stability in all cases.
The greater complexity of the Six Species model yielded very interesting results as we
performed our simulations. As α3 and α4 increase we saw a direct increase in ratio of off-
pathway to on-pathway species. The relationship is linear and explained by B′1/B1 = α3,
and B′n/Bn = α4. The ratio of m′/m is very stable, but when α3, α4 exceeds 7, it appears
to undergo exponential growth. When we increased only α3, we saw that there is an initial
increase in the ratio of off-pathway to on-pathway oligomers, but the curve can be described
as sigmoidal: no matter how high α3 goes, this ratio ceases to grow any higher than 1.
This shows the Bn to B
′
n bridge is critical for formation of n and m species, and can’t be
forced only over the B1 to B
′
1 bridge. This was confirmed by our examination of the Nash
Equilibrium using Model 2.
We were also able to show that we could get any species to outperform on an absolute
basis. Doing this for n and m species required us to increase forward rates to levels, that
weren’t necessarily realistic, but confirmed the ability of the system to be in any particular
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equilibrium state.
Lastly, dynamic simulations of both models, done by increasing the amount of B1 in the
system at regular intervals, saw both the Base Model and Model 2 favoring the formation of
n and m species. With backward and forward rates equal, Model 2 took longer for this to
happen, but even here, the higher order species eventually dominate. It appears that both
of the models have a preference for oligomers over monomers.
4.3 Future Study
There are a few recommendations for future study. Firstly, analyzing stability with the
use of Lyapunov functions might bear some fruit and help to clear up the stability picture of
the 6 Species models. The number of dimensions of the model and the non-linearity could
mean that another approach to stability analysis is needed. It would be a vindication of the
model to be able to show global stability.
Secondly, analyzing a more dynamical model with increased pathways would be of great
interest. The analysis we have made of the Four and Six Species models has given us a
solid understanding of the behavior of the model. Increasing the number of pathways to
aggregation should be the next step in modeling. Currently, we have just n-mers to n-mers,
but this is almost certainly not the case in vivo, where there can be n-mers to m-mers.
Also, our attempt at a more dynamical model in the Numerical Results section of Chapter
3 was rudimentary: we added discrete amounts of new monomers of B1 in set intervals to
simulate an evolving system. The reality of the process is that the formation of new Aβ
from APP is most likely stochastic. Adding randomness to this part of the model would be
a good addition.
Finally, our look at the thermodynamics of the system in chapter 4 was just the beginning
of what we would like to achieve. This area of our study will be expanded upon in future
work.
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